BreezeBio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 63

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $60M

  • Investors
  • 34

BreezeBio General Information

Description

Developer of curative therapies designed for current gene therapy delivery challenges by systematically screening its proprietary nanoparticle library. The company's tool makes therapeutic gene editing possible and is easier to use, faster, and more accurate than previous gene-editing techniques, and also has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases, and also provides safer and more efficient delivery to target tissues.

Contact Information

Website
www.breezebio.com
Formerly Known As
Genedit
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3000 Marina Boulevard
  • Suite 350, Brisbane
  • South San Francisco, CA 94005
  • United States
+1 (510)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • 3000 Marina Boulevard
  • Suite 350, Brisbane
  • South San Francisco, CA 94005
  • United States
+1 (510)

BreezeBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BreezeBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 25-Feb-2026 $60M Completed Generating Revenue
6. Later Stage VC (Series A1) 23-Jan-2024 Completed Generating Revenue
5. Early Stage VC (Series A) 23-Sep-2021 Completed Generating Revenue
4. Grant 29-Jan-2019 Completed Pre-Clinical Trials
3. Seed Round 11-Dec-2018 Completed Pre-Clinical Trials
2. Accelerator/Incubator 22-Mar-2017 $5K $5K Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2016 Completed Startup
To view BreezeBio’s complete valuation and funding history, request access »

BreezeBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-1
Series B
Series B-1 NV
Series B NV
Series A1 NV
Series A1
Series A NV
Series A 8,677,734 $0.000100 $0.19 $3.1 $3.1 1x $3.1 18.28%
Seed 4,560,000 $0.000100 $0.12 $1.97 $1.97 1x $1.97 9.6%
To view BreezeBio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

BreezeBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of curative therapies designed for current gene therapy delivery challenges by systematically screening its pr
Drug Delivery
South San Francisco, CA
63 As of 2026

Menlo Park, CA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BreezeBio Competitors (29)

One of BreezeBio’s 29 competitors is ReCode Therapeutics, a Venture Capital-Backed company based in Menlo Park, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ReCode Therapeutics Venture Capital-Backed Menlo Park, CA
Coave Therapeutics Venture Capital-Backed Paris, France
Aitia Venture Capital-Backed Cambridge, MA
Halozyme Therapeutics Formerly VC-backed San Diego, CA
TriGemX Bio Venture Capital-Backed New York, NY
You’re viewing 5 of 29 competitors. Get the full list »

BreezeBio Patents

  • 54

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 22

    Pending

  • Expiring in next 12 mo

BreezeBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024211596-A1 Sirna compositions targeting scn9a Inactive 04-Apr-2023
CA-3222341-A1 Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups Pending 11-Jun-2021
EP-4352131-A1 Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups Pending 11-Jun-2021
US-20240285781-A1 Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups Pending 11-Jun-2021
WO-2022261561-A1 Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups Inactive 11-Jun-2021 C08G69/10
To view BreezeBio’s complete patent history, request access »

BreezeBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BreezeBio Investors (34)

Investor Name Investor Type Holding Investor Since Participating Rounds
DSC Investment Venture Capital Minority
Kiwoom Investment Venture Capital Minority
STIC Ventures Venture Capital Minority
SV Investment Venture Capital Minority
Yuanta Investment Venture Capital Minority
You’re viewing 5 of 34 investors. Get the full list »

BreezeBio Investments (1)

BreezeBio’s most recent deal was a Later Stage VC with Huons Natural. The deal was made on 05-Dec-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Huons Natural 05-Dec-2023 Later Stage VC Other Consumer Non-Durables
To view BreezeBio’s complete investments history, request access »

Ready to get started?

Request a free trial

BreezeBio FAQs

  • When was BreezeBio founded?

    BreezeBio was founded in 2016.

  • Where is BreezeBio headquartered?

    BreezeBio is headquartered in South San Francisco, CA.

  • What is the size of BreezeBio?

    BreezeBio has 63 total employees.

  • What industry is BreezeBio in?

    BreezeBio’s primary industry is Drug Delivery.

  • Is BreezeBio a private or public company?

    BreezeBio is a Private company.

  • What is the current valuation of BreezeBio?

    The current valuation of BreezeBio is .

  • What is BreezeBio’s current revenue?

    The current revenue for BreezeBio is .

  • How much funding has BreezeBio raised over time?

    BreezeBio has raised $117M.

  • Who are BreezeBio’s investors?

    DSC Investment, Kiwoom Investment, STIC Ventures, SV Investment, and Yuanta Investment are 5 of 34 investors who have invested in BreezeBio.

  • Who are BreezeBio’s competitors?

    ReCode Therapeutics, Coave Therapeutics, Aitia, Halozyme Therapeutics, and TriGemX Bio are some of the 29 competitors of BreezeBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process